Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
9
×
boston blog main
boston top stories
9
×
drugs
9
×
life sciences
national blog main
clinical trials
fda
national top stories
alnylam pharmaceuticals
biotech
new york blog main
new york top stories
patisiran
rna interference
san diego blog main
san diego top stories
akcea therapeutics
aminolevulinic acid
crispr
givosiran
hereditary transthyretin amyloidosis
inotersen
onpattro
paul matteis
san francisco blog main
san francisco top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
aldehyde
aldeyra therapeutics
allergan
allergic conjunctivitis
allopregnanolone
antibiotics
arvinas
astrazeneca
What
medicine
drug
fda
alnylam
rna
interference
new
pharmaceuticals
rnai
ago
data
gene
make
second
seek
speedy
step
uses
way
aldeyra
allergan
approval
approve
approved
approves
awaits
biological
biotechs
blessing
bosley
brexanolone
cells
ceo
cf
check
chose
cleared
clinical
close
closer
Language
unknown
Current search:
drugs
×
boston
×
" boston top stories "
×
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision